COVID-19 spread harder to control without common effort says French PM as daily cases double

French Prime Minister Jean Castex (R), flanked by French Health Minister Olivier Veran (L), gestures as he delivers a speech during a visit at the CHU hospital in Montpellier. (AFP)
Short Url
Updated 11 August 2020

COVID-19 spread harder to control without common effort says French PM as daily cases double

  • French health authorities reported 1,397 new COVID-19 infections over 24 hours on Tuesday
  • New clusters have mushroomed as people let their hair down on holiday, families hold reunions and workers return to offices

PARIS: The renewed spread of coronavirus in France could become harder to control without a collective effort to stop a rise in the infection rate, its prime minister said on Tuesday.
The public was becoming careless, Jean Castex warned, after official data recorded nearly 5,000 new COVID-19 cases from Saturday to Monday. The epidemic has now killed more than 30,300 people in France.
French health authorities reported 1,397 new COVID-19 infections over 24 hours on Tuesday, almost twice Monday’s tally.
The Health Ministry website said there were 15 new deaths in hospital due the disease, compared to an increase of 16 over a three-day period between Monday and Saturday,
“If we don’t act collectively, we expose ourselves to the heightened risk that the rebound in the epidemic becomes hard to control,” Castex said during a visit to a hospital intensive care ward in southern France.
France’s 7-day moving average of new infections climbed to 1,640 on Monday from 1,056 on July 31. The 7-day measure reached a post lockdown low of 272 on May 27, a little over 2 weeks after the government eased one of Europe’s strictest lockdowns.
But as in most neighboring European countries, new clusters have mushroomed as people let their hair down on holiday, families hold reunions and workers return to offices and France is desperate to avoid another full-scale lockdown.
Britain has said it will not hesitate putting more countries on its quarantine list, including France, where hordes of Britons spend their summer vacations.
Earlier on Tuesday, President Emmanuel Macron held a video conference with top ministers from his Riviera summer retreat.
During the meeting, it was decided France would draw up new restrictions for the 20 largest cities to curb the rising infection rate and that a ban on gatherings of more than 5,000 people would be extended until Oct. 31.
Some cities have already taken action. Paris on Monday joined Toulouse, Lille, Biarritz and others in imposing a mandatory face mask order in crowded outdoor zones. They are already compulsory nationwide in shops and banks.
The prime minister said testing was “more than satisfactory,” with more than 600,000 tests being conducted weekly, but said more could still be done to target those with symptoms, the prime minister said.
Talking of the risk of another lockdown, Castex said: “no one wants to live through that again.”


Arthritis drug trialled as potential treatment for COVID-19

Updated 28 September 2020

Arthritis drug trialled as potential treatment for COVID-19

  • Dr. Andy Martin: We are conducting this study to see whether otilimab could potentially ease the effect of COVID- 19 on the lungs
  • Dr. Tim Felton: The primary end point of this study is that participants are alive and free of lung failure after 28 days — so this research is potentially life-saving

LONDON: The experimental arthritis drug, otilimab, is being trialled as a potential treatment for COVID-19.

The first patient, administered with the drug, is currently being cared for at Manchester Royal Infirmary (MRI), part of Manchester University NHS Foundation Trust (MFT).

The OSCAR study (Otilimab in Severe COVID-19 Related Disease) is sponsored and funded by the pharmaceutical company GlaxoSmithKline.

The study at the MRI is being led by Dr. Andy Martin, an Intensive Care and Anaesthesia Consultant.

Dr. Martin said: “The patients eligible to take part in this study are those experiencing very severe lung difficulties due to COVID-19 infection and are receiving oxygen or ventilator support.

“We are conducting this study to see whether otilimab — which is under investigation as a potential treatment for rheumatoid arthritis — could also potentially ease the effect of coronavirus on the lungs, dampening the impact of the virus on the immune system.

Christopher Corsico, Senior Vice President Development, GSK said: “We are continuing to work hard to find solutions to address the pandemic, including exploring potential treatment options for COVID-19 patients.

“We know that some COVID-19 patients experience an overreaction of their immune system — sometimes referred to as cytokine storm — which can lead to hospitalization or death. We believe that otilimab might be able to help counter or calm this process.

Dr. Tim Felton, Honorary Consultant, Senior Lecturer at The University of Manchester and Clinical Lead for all MFT COVID-19-related research studies, leads OSCAR at Wythenshawe Hospital, which is also part of MFT.

Dr. Felton said: “The primary end point of this study is that participants are alive and free of lung failure after 28 days — so this research is potentially life-saving.

“I’d like to thank our first OSCAR participant — as well as the thousands of others who have taken part in coronavirus studies at MFT to date — as every participant who takes part in our research is contributing to the coordinated effort to enhance understanding of this global pandemic.”